Evinova positions itself within the AstraZeneca group as a pharma-for-pharma partner, citing substantial gains in patient experience, trial speed, cost reduction, and data quality.

Evinova unveils an AI-native platform for end-to-end clinical development that uses agentic AI to enhance study design, streamline collaboration, and enable seamless digital data flow aligned with USDM standards, while embedding safeguards for responsible AI use.

The platform emphasizes USDM data standards, governance controls for AI, and a faster, safer, patient-centric development process.

Agentic AI assists in study design, accelerates processes, and integrates robust safeguards to ensure responsible AI usage within USDM-compliant workflows.

Historically, Evinova reports multi-year savings for customers, about six months faster trial delivery, and up to 32% cost reductions, with related outcomes previously published in Nature Medicine.

The release invites pharma, biotech, and CROs to engage with Evinova, offering media contact details for inquiries.

Industry leadership quotes position AI as essential to transforming clinical development, with executives from Evinova and BMS stressing the need to shorten timelines and reduce costs through digital tools.

BMS signs on to optimize its clinical development with Evinova’s AI-native platform, beginning with deploying the Cost Optimizer module across its global portfolio.

The collaboration aims to improve insight-driven decision making, identify productivity opportunities, and enable more efficient trial designs to accelerate drug development and enhance experiences for sites and patients.

Evinova highlights a human-centered product development approach, incorporating feedback from patients and trial site teams, with strong eCOA compliance and engagement metrics.

The platform is globally scalable and has delivered hundreds of millions in multi-year savings, featuring the Unified Trial Solution that connects sponsors, sites, and patients for a connected trial experience.

Unified Trial Solution integrates eCOA, telehealth, and connected devices for remote patient monitoring, enabling novel endpoints and innovative trial designs.